Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
MedPage Today on MSN20h
NCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown ContinuesThe American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
Stocks like India Pesticides, HFCL, NDR Auto Components, JSW Steel, GR Infraprojects, Biocon, Oil and Natural Gas Corporation ...
AstraZeneca Pharma India gets CDSCO nod for durvalumab to treat LS-SCLC: Our Bureau, Bengaluru Monday, March 10, 2025, 15:30 Hrs [IST] AstraZeneca Pharma India, received a Central ...
GlobalData on MSN4d
AstraZeneca reports positive outcomes from trial of ImfinziAstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...
4don MSN
Following approval from the Republic of the Philippines Securities and Exchange Commission, the company's step-down ...
Tata Power, Nazara Tech, Lupin, Biocon, JSW Steel, Shilpa Medicare, and Oriental Rail are some other stocks to watch today, ...
Indian benchmark indices closed relatively flat on Friday, ending their two-day winning streak. The BSE Sensex edged down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback